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Introduction and Rationale
The introduction of routine immunisa-
tion with pneumococcal conjugate vac-
cines (PCVs) in developing countries is
expected to significantly reduce childhood
deaths [1]. The 7-valent pneumococcal
conjugate vaccine (PCV-7), containing
serotypes 4, 6B, 9V, 14, 18C, 19F, and
23F, is highly efficacious against invasive
pneumococcal disease (IPD) of vaccine
serotype, plus serotype 6A [2,3]. Routine
immunisation with PCV-7 has led to dra-
matic decreases in IPD due to pneumo-
cocci of vaccine serotype, but variable
increases in IPD due to pneumococci of
non-vaccine serotype [4–6]. Therefore, it
is essential to monitor the introduction of
PCVs in different settings. Demonstrating
the impact of PCVs will be crucial for
ongoing immunisation policy.
In 2009, the Government of The
Gambia introduced routine PCV-7 vacci-
nation into the national Expanded Pro-
gramme of Immunisation (EPI) with sup-
port from the GAVI Alliance. Three doses
of PCV-7 are given at 2, 3, and 4 months of
age. A limited catch-up campaign gave at
least two doses of vaccine to approximately
50% of children aged 2–11 months and one
dose of vaccine to approximately 10% of
children aged 12–23 months. PCV-13
replaced PCV-7 in April 2011 without a
catch-up campaign.
The importance of pneumococcal dis-
ease in The Gambia was indicated by a
16% reduction in all-cause mortality in
children 2–29 months of age in a trial of
PCV-9 conducted in Upper and Central
River Regions [7]. There was a 71% re-
duction in IPD of vaccine serotype and a
35% reduction in radiological pneumo-
nia. The incidence of IPD and radiolog-
ical pneumonia in the placebo arm was
390 per 100,000 person years and 37 per
1,000 person years, respectively. The
incidence of IPD in this part of The
Gambia was estimated previously to be
554 and 240 per 100,000 person years in
under 1 and under 5 year-old children,
respectively [7]. Neither the burden of
IPD, nor the extent of the indirect (herd)
effect of PCVs, are known in older
children and adults in The Gambia,
although PCV-7 vaccination of Gambian
infants has recently been shown to reduce
carriage of vaccine serotypes in older
subjects [8].
Serotype coverage of IPD in The
Gambia with PCV-7 and PCV-13 is
approximately 30% and 70%, respective-
ly [9]. Consequently, there is a large
reservoir of pneumococci of non-vaccine
serotypes available for replacement [10].
We developed a surveillance system to
monitor the incidence of vaccine and
non-vaccine type IPD and radiological
pneumonia in those aged 2 months and
older, before and after the introduction of
PCVs. The data, when available, will
provide key information to support PCV
immunisation policy in The Gambia and
elsewhere in Africa. Here we describe
how this surveillance system was set up
and is being operated.
Purpose
The surveillance system monitors two
key outcome measures before and after the
introduction of PCVs: (1) the incidence of
IPD due to vaccine and non-vaccine
serotypes and (2) the incidence of radio-
logical pneumonia. Secondary aims are to
monitor: (1) pneumococcal antimicrobial
resistance and (2) child mortality.
The Health in Action section is a forum for
individuals or organizations to highlight their
innovative approaches to a particular health prob-
lem.
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Population under Surveillance
Surveillance Site
The Gambia is a small West African
country of 1.5 million people. The sur-
veillance system was established in the
Upper River Region and is integrated with
the local health system. The only major
health centre in the Upper River Region is
in the town of Basse, serving a largely rural
population of approximately 191,000 peo-
ple on both banks of the river Gambia.
The Basse Health and Demographic
Surveillance System (BHDSS) is restricted
to the population on the south bank of the
river (Figure 1). Five peripheral clinics in
the BHDSS area provide inpatient and
outpatient care and refer patients to Basse
health centre.
Demographic Surveillance
To provide precise estimates of the
population denominator, demographic sur-
veillance commenced in July 2007 with
visits to each household every 4 months.
The total population initially enumerated
was 136,387. All deaths, births, in- and out-
migrations, pregnancies and marriages, and
the vaccination status of the children, are
recorded during visits. Verbal autopsies are
conducted using questionnaires designed
by the INDEPTH Network (http://www.
indepth-network.org). The Global Position-
ing System coordinates of all households
have been recorded.
Sample Size Considerations
We estimated that the surveillance
system would identify approximately 75
cases of IPD in children under 5 years of
age per year [7], 45 of whom would be
under 2 years of age, prior to the
Summary Points
N Routine use of pneumococcal conjugate vaccines (PCVs) in developing
countries is expected to lead to a significant reduction in childhood deaths.
However, PCVs have been associated with replacement disease with non-
vaccine serotypes.
N We established a population-based surveillance system to document the direct
and indirect impact of PCVs on the incidence of invasive pneumococcal disease
(IPD) and radiological pneumonia in those aged 2 months and older in The
Gambia, and to monitor changes in serotype-specific IPD.
N Here we describe how this surveillance system was set up and is being
operated as a partnership between the Medical Research Council Unit and the
Gambian Government.
N This surveillance system is expected to provide crucial information for
immunisation policy and serves as a potential model for those introducing
routine PCV vaccination in diverse settings.
Figure 1. Map of catchment area for the surveillance system in The Gambia, including settlements, primary health care (PHC), and
other health facilities.
doi:10.1371/journal.pmed.1001161.g001
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introduction of PCV-7 [3]. Using inci-
dence data from the placebo arm of the
PCV-9 trial in The Gambia, we calculated
that we would have approximately 85%
power to detect a 50% decrease in vaccine
type IPD in under 2-year-old children
over 2 years of before and after surveil-
lance, at the 5% level of significance. We
calculated that we would have over 90%
power to detect a 20% reduction in
radiological pneumonia in children under
2 years old and 60%–70% power to detect
a 40% increase in non-vaccine type IPD.
Increased power of the study has resulted
from extension beyond 2 years of follow-
up and the growth in the population under
surveillance to over 160,000 in 2011. In
addition, the introduction of the higher
valency PCV-13 (containing the additional
serotypes 1, 3, 5, 6A, 7F, and 19A) in mid-
2011, should further reduce vaccine type
IPD and radiological pneumonia. Sample
size considerations assumed vaccination
coverage of over 85%.
Case Definitions and Screening
Criteria
Case definitions. Case definitions
were developed to ensure international
comparability while being measurable local-
ly (Table 1). IPD includes any case of
clinically suspected pneumonia, meningitis,
or septicaemia from whom S. pneumoniae is
isolated from a normally sterile site. The
case definition for radiological pneumonia is
aligned to the World Health Organization
(WHO) consensus definition, as used pre-
viously [3,11].
Screening criteria for nursing assess-
ment. Figure 2 illustrates the flow from
presentation of a case to formal reporting of
the clinical and laboratory data. All in-
dividuals in the BHDSS population who
present to health facilities at any time of day
are evaluated by a dedicated surveillance
system nurse to determine if referral to a
surveillance system clinician at Basse is
indicated. The nurses also conduct daily
rounds of all inpatients to identify any cases
missed at outpatient screening or who have
developed criteria for referral. Criteria for
referral are presented in Table 2, and these
took into consideration the capabilities of
local nurses. Separate criteria were developed
for patients aged 2–59months and for those 5
years and older. Patients who do not meet
referral criteria proceed to evaluation and
treatment by other health facility staff.
Screening criteria for clinical assess-
ment. Patients referred by the nurses are
evaluated by clinicians using clinical criteria
for suspected pneumonia, meningitis, and
Table 1. Case definitions for pneumonia, meningitis, and septicaemia.
Syndrome Case Definition
Bacterial pneumonia A suspected case of pneumonia with confirmed aetiology by isolation of
bacteria from a normally sterile site (e.g., blood, pleural fluid, or lung aspirate)
Radiological pneumonia A suspected case of pneumonia with changes on chest X-ray that meet
WHO standard criteria for end-point consolidation
Meningitis A suspected case of meningitis with confirmed bacterial aetiology from
CSF or blood
Septicaemia A suspected case of pneumonia, meningitis, or septicaemia with
confirmed aetiology by isolation of pathogenic bacteria from the blood
doi:10.1371/journal.pmed.1001161.t001
Figure 2. Flow chart for the Gambian pneumococcal surveillance system.
doi:10.1371/journal.pmed.1001161.g002
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septicaemia (Table 3). These were derived
from WHO definitions [12] and previous
studies [3,7]. In addition, cough and/or
difficulty breathing with an oxygen satura-
tion ,92% on breathing air was included as
a criterion for suspected pneumonia [13]. We
adapted criteria for lumbar puncture from a
study of adults in Malawi [14]. For children
under 5 years of age, severe malnutrition
was included as an indication for blood
culture [15].
We initially adopted a temperature
criterion of ,36uC or $38uC for referral
as a suspected case of bacteraemia, follow-
ing a previous study in Gambian children
[16]. However, because this criterion
overwhelmed the surveillance capacity
during piloting, with little added yield of
cases of IPD, it was applied to inpatients
only. Similarly, ‘‘excessive crying’’ was
omitted because of a low yield and a large
number of inappropriate referrals.
These criteria are applied in the pres-
ence of sound clinical judgement. In
particular clinicians are trained that clin-
ical judgement plays an important role in
identifying patients who might have men-
ingitis (Table 3). Clinical assessment results
in diagnoses of suspected pneumonia,
meningitis, septicaemia, or combinations
of the three. Standardised investigations
are performed on the basis of the surveil-
lance diagnosis. Most specimens and all X-
rays are taken at Basse Health Centre. If
necessary, blood cultures are collected at
peripheral clinics prior to antibiotic ad-
ministration and transport of the patient.
Lung aspiration is undertaken on children
with dense and accessible peripheral con-
solidation on chest X-ray after informed
consent.
Implementation of the Surveillance
System
Situational analysis. We conducted
pre-surveillance site evaluations of clinical
and laboratory facilities, including evaluation
of patient referral and investigation, tran-
sport, electricity supply, staff expertise and
training, and existing clinic and laboratory
infrastructure. We reviewed patient flows
and the systems employed for their transport
between facilities.
Project management. We used a
project management framework to set up
the surveillance system. Figure 3 shows
each line of activity as a series of de-
pendency relationships, which were then
prioritised according to estimated time to
completion. We aimed to complement
routine assessment and management, whi-
le strengthening existing clinical and
laboratory services. We organised meet-
ings at central, regional, and local level,
and developed plans in collaboration with
staff at clinics, the health centre, and the
regional health office. We explained the
nature and purpose of the project
employing oral and visual presentations
at community events and answered
participants’ questions.
Facilities. A system was established to
transport patients referred to Basse Health
Centre for clinical evaluation and a separate
space was established at the health centre for
the assessment. A digital X-ray system was
established for pneumonia surveillance. The
MRC Basse laboratory performs all mi-
crobiological analyses. The MRC labo-
ratory on the coast performs serotyping
and is a WHO reference site for pneu-
mococcal bacteriology and serotyping.
Staff and staff training. On
average, four clinicians (all based in
Basse) and 16 nurses (11 based in Basse)
are employed on the surveillance team,
along with auxiliary staff and a medically
trained epidemiologist. Surveillance staff
are located at each health facility serving
the BHDSS population. A radiographer,
trained for previous studies, was retained
and employed to work on the surveillance
system. Training was given to project
staff on assessment of patients using
surveillance criteria through oral and
visual presentations and written material.
Training is continuing as frequent turn-
over of staff, especially clinicians, is a
challenge in The Gambia.
Table 2. Criteria developed for nurses to identify patients who should be referred to a clinician for assessment of suspected
pneumonia, meningitis, or septicaemia.
Criteria Definitiona
$2 Months and ,5 Years $5 Years
History of cough or difficulty breathing, AND raised respiratory rate for ageb History of cough and difficulty breathing
Axillary temperature of at least 38uC, or less than 36uC in a patient admitted or being admitted History of cough and pleuritic chest pain
History of convulsion History of cough and supraclavicular/sternal recession or nasal flaring
Impaired consciousnessc History of productive cough and fever
Bulging fontanelle History of rigors
Stiff neck History of seizure
Prostrationd Impaired consciousnessc
Lower chest wall indrawing, nasal flaring, or grunting Altered mental state
Oxygen saturation less than 92% Axillary temperature of at least 38uC or less than 36uC in a patient
admitted or being admitted or
Weight below 23 z-score for age Photophobia
Local musculoskeletal swelling or tenderness Neck stiffness
Any child with suspected meningitis Local musculoskeletal swelling or tenderness
— Any patient with suspected meningitis
aTo be referred for further assessment if one or more of the following are present for 14 days or less.
bRaised respiratory rate for age is defined as greater than 50 breaths per minute for children at least 2 months but less than 12 months, and as greater than 40 breaths
per minute for children at least 12 months but less than 60 months.
cImpaired consciousness is defined as V, P, or U on the AVPU score, where A is if the patient is alert, V if responsive to verbal stimulus, P if responsive to pain stimulus,
and U if unresponsive.
dProstration is defined as inability to drink or breast feed, or to remain sitting in a child otherwise able to sit.
doi:10.1371/journal.pmed.1001161.t002
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Data management and analysis.
Nurses complete screening forms for
each patient referred to a clinician.
Clinicians complete case report forms
and investigation request forms. Nurse
coordinators take all these forms and
specimens to the data management team
and laboratory respectively (Figure 2).
Specific forms have been created for
microbiological analysis and serotyping.
Data are double entered and backed up,
and paper forms are stored securely. All
laboratory and radiological information
are fed back by nurse coordinators to those
responsible for the patients’ clinical
management. Formal classification of X-
rays is conducted at a later date by trained
clinicians blinded to the date of inves-
tigation. The data management team
produces 3-monthly reports to a steering
committee that grants access to the data to
investigators and others as requested. The
reports include analyses of the main and
secondary outcomes and the numbers of
suspected and confirmed cases. Formal
publication of pre- and post-vaccine in-
troduction data will be in peer-reviewed
open access journals.
Piloting. After a 1-year preparation pe-
riod, we established surveillance progressively
over a 7-month piloting period. During
this time, we screened over 1,000 pa-
tients among whom 37 cases of IPD
were identified. As a result, minor
adjustments were made to the system, in-
cluding to the screening criteria, forms,
and standard operating procedures. Key
areas for further training of staff were
identified and appropriate training pro-
vided. A lack of awareness of the sur-
veillance system among non-surveillance
clinic staff was identified and addressed.
Formal surveillance began on 12 May
2008.
Cost. The capital cost of establishing
the system was approximately US$500,000
with annual expenditure of approximately
US$1.3 million. While the surveillance
system provides clinical and laboratory
investigations for those presenting to
health centres with suspected IPD, their
Table 3. Clinical criteria for suspected pneumonia, meningitis, and septicaemia.
Suspected
Condition Criteria Definition
$2 Months and ,5 Years $5 Years
Suspected
pneumonia
Pneumonia is suspected if there
is a history of cough or difficulty
breathing of less than 14 days’
duration, accompanied by one
or more of:
1. Raised respiratory rate for agea Pneumonia is suspected in patients
presenting with an illness of 14
days’ duration or less, if two or
more of the following are present:
1. Cough
2. Lower chest wall indrawing, nasal
flaring, or grunting
2. Haemoptysis
3. Oxygen saturation less than 92% 3. Pleuritic chest pain
4. Focal chest signs (dull percussion
note, coarse crackles, bronchial breathing)
4. Breathlessness
— 5. Axillary temperature
$38uC
Suspected
meningitis
Meningitis is suspected if
the patient is clinically
unwell and if any of the
following are present:
1. Neck stiffness Meningitis is suspected if the
patient is clinically unwell and
if two or more of the following
are present:
1. Axillary temperature
$38uC
2. Impaired consciousnessb 2. Meningism (neck stiffness
and/or photophobia)
3. Prostrationc 3. Altered mental state
(Glasgow Coma Score ,4)
4. History of convulsion —
5. Bulging fontanelle —
Suspected
septicaemia
Septicaemia is suspected
if one or more of the
following is present:
1. Clinician diagnosis of focal sepsis
(including but not limited to: septic
arthritis, osteomyelitis, endocarditis,
peritonitis, liver abscess, soft tissue
abscess, cellulitis)
Septicaemia is suspected
if one or more of the
following is present:
1. Clinician diagnosis of
focal sepsis (including but
not limited to: septic
arthritis, osteomyelitis,
endocarditis, peritonitis,
liver abscess, soft tissue
abscess, cellulitis)
2. Axillary temperature is ,36uC or
$38uC and no obvious cause of fever
2. Axillary temperature is
,36uC or $38uC and no
obvious cause of fever
3. For a patient admitted, or being
admitted, the clinical impression is
of severe malnutritiond.
3. History of rigors
aRaised respiratory rate for age is defined as greater than 50 breaths per minute for children at least 2 months but less than 12 months, and as greater than 40 breaths
per minute for children at least 12 months but less than 60 months.
bImpaired consciousness is defined as V, P, or U on the AVPU score, where A is if the patient is alert, V if responsive to verbal stimulus, P if responsive to pain stimulus,
and U if unresponsive.
cProstration is defined as inability to drink or breast feed, or to remain in a seated position in a child otherwise able to do so.
dSevere malnutrition is defined according to the WHO definition.
doi:10.1371/journal.pmed.1001161.t003
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Figure 3. Project management for the establishment of the Gambian pneumococcal surveillance system: major dependency
relationships.
doi:10.1371/journal.pmed.1001161.g003
Table 4. Pneumococcal surveillance system attributes.
Attribute Comment
Simplicity Clear process for defining and investigating patients.
Limited number of investigations to be considered.
Limited sources of information (field, clinic, and laboratory).
Limited follow-up of cases.
Standardised data entry processes.
Little modification of data required prior to reporting.
Some complexity working within and alongside government systems.
Standard operating procedures and active management is required to ensure consistent results.
Flexibility Interlocking research projects addressing clinical and laboratory questions are possible.
Able to accommodate research projects on other pathogens/diseases within the Demographic Surveillance System.
Data quality Completeness is evaluated as a performance indicator and validity through clinical review of diagnosed cases
Acceptability High individual and population level participation in the demographic surveillance system and case ascertainment procedures.
High level collaboration with government agencies.
Documentation of patient refusals, form completion, form completeness, reporting rates.
Sensitivity The criteria for investigation may miss cases of pneumococcal disease.
Investigative tools are likely to miss a proportion of true cases of pneumococcal disease with some indication of this provided by (a)
monitoring radiological pneumonia and (b) specific study of blood cultures in all under 5 hospital admissions.
Predictive value positive False positive cases minimised by tight case definitions and laboratory standards. Only a proportion of radiological pneumonia is due
to pneumococcus.
Representativeness Population-based surveillance enhances representativeness.
Timeliness Limited only by time to culture positivity and data entry and validation.
Stability Indicators have been established to monitor system performance over time.
doi:10.1371/journal.pmed.1001161.t004
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treatment is undertaken by the government
health system.
Ethics. While the majority of the ac-
tivities of the surveillance system are simply
enhanced routine care, specific patient
consent is obtained for any invasive pro-
cedures (such as lung aspiration), for storage
of samples for future analysis, and for secure
storage of identifiable records.
Evaluation of the Surveillance
System
System attributes. Table 4 shows
the attributes of the system according to
US Centers for Disease Control (CDC)
evaluation guidelines [17]. These do not
include demonstration of the cost-
effectiveness of the system and no formal
evaluation of this is planned. Standard
operating procedures were written for all
activities. Interlocking projects include
studies of other pathogens and molecular
characterisation of pneumococcal isolates.
Conventional microbiology provides
pneumococcal isolates for serotyping.
However, blood culture has sensitivity for
IPD of less than 50% [18]. While two-
thirds or more of lower respiratory tract
infections have a normal chest X-ray
[3,19], radiological pneumonia has been
a useful primary outcome in efficacy trials
[3]. A clinical diagnosis of pneumonia has
been useful for estimating the preventable
burden of disease [20].
Laboratory-based systems, and hospital
record-based reports, are vulnerable to
bias from changing practice [21]. The
Gambian surveillance system monitors
numbers of patients presenting and has
standardised clinical, radiological, and
laboratory procedures. The microbiologi-
cal methods have been consistent over
time ensuring data comparability between
studies in The Gambia. The surveillance
area is typical of large areas of sub-
Saharan Africa. However, international
comparisons need to take into account
local characteristics such as HIV preva-
lence, which is estimated to be less than
2% in The Gambia.
Performance indicators. Table 5
shows the performance indicators that
were developed and the methods used
for measuring them [21]. Vaccine supply
and delivery are evaluated as part of the
assessment of vaccine effectiveness [22].
We produce regular checklists for
equipment, staff, sample transport, and
other indicators. We developed clinical, X-
ray and laboratory log books to enhance
consistency between completed forms and
data entry. Regular measurement of these
indicators facilitates ongoing quality
control and the identification of obstacles
to the smooth running of the system.
Obstacles identified include turnover of
staff, laboratory contamination, misun-
derstandings between surveillance staff
and other staff at the clinics, and the
logistics of referral and transport of
patients. In addition, external factors,
such as flooding in the wet season, can
affect performance.
Conclusions
Our surveillance system has been estab-
lished to document the direct and indirect
Table 5. Performance indicators for the Gambian pneumococcal surveillance system and the methods for measuring them.
Performance Area Indicator Method
Vaccine-specific Vaccine supply Regular checks of vaccine supply log books/information systems
Vaccine delivery Random check of cold-chain system
Vaccine coverage Biennial surveys of random sample of children with review of health card for vaccine delivery
Impact on other vaccines Other vaccine coverage Biennial surveys of random sample of children with review of health card for delivery of other vaccines
Demographic surveillance Proportion of the population
absent or travelling
Annual review of data from each DSS round to show proportion and trends
Case Identification Proportion of patients with
suspected pneumonia, meningitis,
and septicaemia that are referred
Regular document review of nursing records
Completeness of form filling Manual review of filled forms
Proportion of all IPD that is
identified by the system
Focused study of blood cultures for all those admitted to hospital
Proportion of those referred
for investigation that are
adequately investigated
Clinical notes review
Specimen processing Proportion of blood cultures taken
prior to administration of antibiotics
History of antibiotic use recorded on clinical form and entered into database; time of sample
collection and of administration of antibiotics routinely recorded and entered into database
Proportion of samples reaching the
laboratory within 3 h of collection
Time of receipt recorded on forms, details recorded on database
Proportion of specimens collected
that have results
Review of clinical and laboratory records
Proportion of blood culture
specimens that have no result
due to contamination
Monthly review of blood culture results and specific clinical and laboratory investigation of
contamination rates above 10% of specimens.
Proportion of pneumococcal
isolates with serotyping results
Review of laboratory records
Radiology Proportion of X-rays of
acceptable quality
Reporting of X-rays with quality recorded
Data management Data entry error rate Data cleaning and verification with monthly reports
Timeliness Time recorded for data to become available for reporting
doi:10.1371/journal.pmed.1001161.t005
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impact of PCVs on the incidence of IPD
and radiological pneumonia in The Gam-
bia. The system is expected to provide
crucial information for immunisation pol-
icy and to serve as a model for those
introducing routine PCV vaccination in
diverse settings. It would be helpful if a
similar system could be established in a
few key locations globally. Evidence of
sustained reduction of IPD and radiolog-
ical pneumonia due to PCVs is important
to justify their introduction and ongoing
use. Identification of emerging pneumo-
coccal serotypes may also assist the design
of future PCVs. Key features of a robust
system include standardised case defini-
tions and criteria for screening, investiga-
tion, and reporting. It is also important to
identify whether available census informa-
tion can provide reliable estimates of
denominator populations for the calcula-
tion of incidence rates, in areas where
there is no demographic surveillance
system. Over the first 2 years of surveil-
lance, 3,938 suspected cases of pneumo-
coccal disease aged 2–59 months, and 707
aged 5 years and over, were screened in
the Basse pneumococcal surveillance sys-
tem. It is expected that the first detailed
results from this project will be peer-
reviewed and published in 2012 and that
the project will continue until at least
2015.
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